$PTPI News

Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position

Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets

Petros Pharmaceuticals shares are trading lower after the company announced a transition from the Nasdaq to OTC markets.

Petros Pharmaceuticals shares are trading lower after the company announced a transition from the Nasdaq to OTC markets.

Petros Pharmaceuticals Announces Transition From NASDAQ To OTC Markets At The Open Of Trading On Thursday, May 22, 2025

Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer

Petros Pharmaceuticals Partners With Innolitics To Integrate Its Capabilities In The Development Of a SaaS Platform

Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform

Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches

Petros Pharmaceuticals Develops Licensable AI-Enabled SaaS Platform To Help Industry Comply With Trump's MAHA Executive Order By Facilitating FDA-Guided Rx-To-OTC Drug Approvals Through A Smart Health Tech System

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms

Petros Pharmaceuticals Full Year 2024 Earnings: US$3.34 loss per share (vs US$6.35 loss in FY 2023)

Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications

Petros Pharmaceuticals Announces A Collaboration With Renowned Big Data And Analytics Leader To Enhance The Development Of Its Proprietary Technology Solutions Designed To Facilitate Rx-To-OTC Switches For Pharmaceutical Products

Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study

Petros Pharmaceuticals Announces Top-line Results Of Expanded Application Comprehension Study

Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules